Bamet-UD2 is a novel bile acid-platinum derivative.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Lepirudin | The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Bamet-UD2. |
| Bivalirudin | The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Bamet-UD2. |
| Alteplase | The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Bamet-UD2. |
| Urokinase | The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Bamet-UD2. |
| Reteplase | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Bamet-UD2. |
| Anistreplase | The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Bamet-UD2. |
| Tenecteplase | The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Bamet-UD2. |
| Drotrecogin alfa | The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Bamet-UD2. |
| Streptokinase | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Bamet-UD2. |
| Dicoumarol | The risk or severity of bleeding and bruising can be increased when Dicoumarol is combined with Bamet-UD2. |
| Argatroban | The risk or severity of bleeding and bruising can be increased when Argatroban is combined with Bamet-UD2. |
| Ardeparin | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Bamet-UD2. |
| Phenindione | The risk or severity of bleeding and bruising can be increased when Phenindione is combined with Bamet-UD2. |
| Fondaparinux | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Bamet-UD2. |
| Warfarin | The risk or severity of bleeding and bruising can be increased when Warfarin is combined with Bamet-UD2. |
| Pentosan polysulfate | The risk or severity of bleeding and bruising can be increased when Pentosan polysulfate is combined with Bamet-UD2. |
| Phenprocoumon | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Bamet-UD2. |
| Heparin | The risk or severity of bleeding and bruising can be increased when Heparin is combined with Bamet-UD2. |
| Enoxaparin | The risk or severity of bleeding and bruising can be increased when Enoxaparin is combined with Bamet-UD2. |
| Acenocoumarol | The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Bamet-UD2. |
| 4-hydroxycoumarin | The risk or severity of bleeding and bruising can be increased when 4-hydroxycoumarin is combined with Bamet-UD2. |
| Coumarin | The risk or severity of bleeding and bruising can be increased when Coumarin is combined with Bamet-UD2. |
| Ximelagatran | The risk or severity of bleeding and bruising can be increased when Ximelagatran is combined with Bamet-UD2. |
| Desmoteplase | The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Bamet-UD2. |
| Ancrod | The risk or severity of bleeding and bruising can be increased when Ancrod is combined with Bamet-UD2. |
| Rivaroxaban | The risk or severity of bleeding and bruising can be increased when Rivaroxaban is combined with Bamet-UD2. |
| Sulodexide | The risk or severity of bleeding and bruising can be increased when Sulodexide is combined with Bamet-UD2. |
| Semuloparin | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Bamet-UD2. |
| Idraparinux | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Bamet-UD2. |
| Astaxanthin | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Bamet-UD2. |
| Apixaban | The risk or severity of bleeding and bruising can be increased when Apixaban is combined with Bamet-UD2. |
| Otamixaban | The risk or severity of bleeding and bruising can be increased when Otamixaban is combined with Bamet-UD2. |
| Amediplase | The risk or severity of bleeding and bruising can be increased when Amediplase is combined with Bamet-UD2. |
| Dabigatran etexilate | The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Bamet-UD2. |
| Danaparoid | The risk or severity of bleeding and bruising can be increased when Danaparoid is combined with Bamet-UD2. |
| Dalteparin | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Bamet-UD2. |
| Tinzaparin | The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Bamet-UD2. |
| (R)-warfarin | The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Bamet-UD2. |
| Ethyl biscoumacetate | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Bamet-UD2. |
| Nadroparin | The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Bamet-UD2. |
| Ditazole | The risk or severity of bleeding and bruising can be increased when Ditazole is combined with Bamet-UD2. |
| Edoxaban | The risk or severity of bleeding and bruising can be increased when Edoxaban is combined with Bamet-UD2. |
| Sodium citrate | The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Bamet-UD2. |
| Dextran | The risk or severity of bleeding and bruising can be increased when Dextran is combined with Bamet-UD2. |
| Bemiparin | The risk or severity of bleeding and bruising can be increased when Bemiparin is combined with Bamet-UD2. |
| Parnaparin | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Bamet-UD2. |
| Desirudin | The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Bamet-UD2. |
| Antithrombin Alfa | The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Bamet-UD2. |
| Protein C | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Bamet-UD2. |
| Antithrombin III human | The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Bamet-UD2. |
| Letaxaban | The risk or severity of bleeding and bruising can be increased when Letaxaban is combined with Bamet-UD2. |
| Darexaban | The risk or severity of bleeding and bruising can be increased when Darexaban is combined with Bamet-UD2. |
| Betrixaban | The risk or severity of bleeding and bruising can be increased when Betrixaban is combined with Bamet-UD2. |
| Nafamostat | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Bamet-UD2. |
| Monteplase | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Bamet-UD2. |
| Gabexate | The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Bamet-UD2. |
| Fluindione | The risk or severity of bleeding and bruising can be increased when Fluindione is combined with Bamet-UD2. |
| Protein S human | The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Bamet-UD2. |
| Brinase | The risk or severity of bleeding and bruising can be increased when Brinase is combined with Bamet-UD2. |
| Clorindione | The risk or severity of bleeding and bruising can be increased when Clorindione is combined with Bamet-UD2. |
| Diphenadione | The risk or severity of bleeding and bruising can be increased when Diphenadione is combined with Bamet-UD2. |
| Tioclomarol | The risk or severity of bleeding and bruising can be increased when Tioclomarol is combined with Bamet-UD2. |
| Melagatran | The risk or severity of bleeding and bruising can be increased when Melagatran is combined with Bamet-UD2. |
| Saruplase | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Bamet-UD2. |
| (S)-Warfarin | The risk or severity of bleeding and bruising can be increased when (S)-Warfarin is combined with Bamet-UD2. |
| Tocopherylquinone | The risk or severity of bleeding and bruising can be increased when Tocopherylquinone is combined with Bamet-UD2. |
| Dabigatran | The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Bamet-UD2. |
| Troxerutin | The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Bamet-UD2. |
| Edetic acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Bamet-UD2. |
| Reviparin | The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Bamet-UD2. |
| Dermatan sulfate | The risk or severity of bleeding and bruising can be increased when Dermatan sulfate is combined with Bamet-UD2. |
| SR-123781A | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Bamet-UD2. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Bamet-UD2. |
| Eptifibatide | The risk or severity of adverse effects can be increased when Eptifibatide is combined with Bamet-UD2. |
| Ticlopidine | The risk or severity of adverse effects can be increased when Ticlopidine is combined with Bamet-UD2. |
| Anagrelide | The risk or severity of adverse effects can be increased when Anagrelide is combined with Bamet-UD2. |
| Clopidogrel | The risk or severity of adverse effects can be increased when Clopidogrel is combined with Bamet-UD2. |
| Tirofiban | The risk or severity of adverse effects can be increased when Tirofiban is combined with Bamet-UD2. |
| Pentoxifylline | The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Bamet-UD2. |
| Acetylsalicylic acid | The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Bamet-UD2. |
| Dipyridamole | The risk or severity of adverse effects can be increased when Dipyridamole is combined with Bamet-UD2. |
| Sulfinpyrazone | The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Bamet-UD2. |
| Cilostazol | The risk or severity of adverse effects can be increased when Cilostazol is combined with Bamet-UD2. |
| Ridogrel | The risk or severity of adverse effects can be increased when Ridogrel is combined with Bamet-UD2. |
| Epoprostenol | The risk or severity of adverse effects can be increased when Epoprostenol is combined with Bamet-UD2. |
| Resveratrol | The risk or severity of adverse effects can be increased when Resveratrol is combined with Bamet-UD2. |
| Nimesulide | The risk or severity of adverse effects can be increased when Nimesulide is combined with Bamet-UD2. |
| Tesmilifene | The risk or severity of adverse effects can be increased when Tesmilifene is combined with Bamet-UD2. |
| Defibrotide | The risk or severity of adverse effects can be increased when Defibrotide is combined with Bamet-UD2. |
| Beraprost | The risk or severity of adverse effects can be increased when Beraprost is combined with Bamet-UD2. |
| Ibudilast | The risk or severity of adverse effects can be increased when Ibudilast is combined with Bamet-UD2. |
| Andrographolide | The risk or severity of adverse effects can be increased when Andrographolide is combined with Bamet-UD2. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bamet-UD2. |
| Prasugrel | The risk or severity of adverse effects can be increased when Prasugrel is combined with Bamet-UD2. |
| Cangrelor | The risk or severity of adverse effects can be increased when Cangrelor is combined with Bamet-UD2. |
| Tranilast | The risk or severity of adverse effects can be increased when Tranilast is combined with Bamet-UD2. |
| Triflusal | The risk or severity of adverse effects can be increased when Triflusal is combined with Bamet-UD2. |
| Ticagrelor | The risk or severity of adverse effects can be increased when Ticagrelor is combined with Bamet-UD2. |
| Icosapent ethyl | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Bamet-UD2. |
| Vorapaxar | The risk or severity of adverse effects can be increased when Vorapaxar is combined with Bamet-UD2. |